Researcher
Piet GEUSENS
- Keywords:Biomedical sciences (incl. biochemistry)
- Disciplines:Immunology not elsewhere classified
Affiliations
- Immunology & Infection (Department)
Member
From1 Jan 2020 → 15 Oct 2021 - Immunology & Infection (Research group)
Member
From1 Jan 2020 → 15 Oct 2021 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Feb 2012 → 15 Oct 2021 - Biomedical Research Institute (Research institute)
Member
From1 Feb 2012 → 15 Oct 2021 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Feb 2012 → 31 Dec 2019 - Immunology - Biochemistry (Research group)
Member
From1 Feb 2012 → 31 Dec 2019 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Oct 2003 → 30 Sep 2011 - Biomedical Research Institute (Research institute)
Member
From22 Nov 2000 → 30 Sep 2011 - Immunology - Biochemistry (Research group)
Member
From1 Jan 1999 → 30 Sep 2011 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Jan 1999 → 30 Sep 2011 - Medical Basic Sciences (Division)
Member
From1 Jan 1999 → 30 Sep 2009
Projects
1 - 1 of 1
- T lymphocytes: from basic biology to immunotherapyFrom1 Oct 2012 → 31 Dec 2017Funding: IUAP-VII
Publications
31 - 40 of 206
- Prevalence of Sarcopenia in Patients with a Recent Fracture According to the revised EWGSOP definition(2019)
Authors: Caroline E. Wyers, Lisanne Vranken, Irma J. A. de Bruin, Robert Y. van der Velde, Heinrich M. J. Janzing, Sjoerd Kaarsemaker, Piet GEUSENS, Joop VAN DEN BERGH
Pages: 277 - 278 - AUTOANTIBODIES TO THREE NOVEL PEPTIDES IN EARLY AXIAL SPONDYLOARTHRITIS IN TWO INDEPENDENT COHORTS(2019)
Authors: Dana QUADEN, Patrick VANDORMAEL, Piet GEUSENS, Johan VANHOOF, Kurt de Vlam, Veerle SOMERS
Pages: 863 - 864 - SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL(2019)
Authors: Philip J. Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Juergen Rech, Stephen Hall, Piet GEUSENS, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, et al.
Pages: 917 - 917 - DOES A TREAT-TO-TARGET STRATEGY APPLY IN THE MANAGEMENT OF PATIENTS WITH FRAGILITYFRACTURES? A EUROPEAN OVERVIEW(2019)
Authors: T. Thomas, E. Casado, Piet GEUSENS, W. Lems, C. Hofbauer
Pages: S632 - S633 - Multimorbidity and long-term mortality following a specific fragility fracture: Latent class analysis of a nationwide population-based cohort(2019)
Authors: Thash S. Tran, Dana Bliuc, Louise Hansen, Bo Abrahamsen, Joop VAN DEN BERGH, John A. Eisman, Tineke van Geel, Piet GEUSENS, Peter Vestergaard, Tuan V. Nguyen, et al.
Pages: 385 - 386 - All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture(2019)
Authors: I. J. A. de Bruin, C. Klop, C. E. Wyers, J. A. Overbeek, Piet GEUSENS, Joop VAN DEN BERGH, J. H. M. Driessen, F. de Vries
Pages: 573 - 581 - Balancing benefits and risks in the era of biologics(2019)
Authors: Giovanni Adami, Kenneth G. Saag, Roland D. Chapurlat, Nuria Guanabens, Glenn Haugeberg, Willem F. Lems, Radmila Matijevic, Nicola Peel, Denis Poddubnyy, Piet GEUSENS
- Complementarity of Cohort Studies and Randomized Controlled Trials(2019)
Authors: John A. Eisman, Piet GEUSENS, Joop VAN DEN BERGH
Pages: 1769 - 1770 - Comments on Kanis et al.: Characteristics of recurrent fractures(2019)
Authors: Piet GEUSENS, Joop VAN DEN BERGH
Pages: 529 - 530 - SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL(2019)
Authors: Hasan Tahir, Philip J. Mease, Arthur Kavanaugh, Andreas Reimold, Juergen Rech, Stephen Hall, Piet GEUSENS, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, et al.
Pages: 151 - 151